RT Journal Article
SR Electronic
T1 Novel blood test for early biomarkers of preeclampsia and Alzheimer’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.19.21253961
DO 10.1101/2021.03.19.21253961
A1 Cheng, Shibin
A1 Banerjee, Sayani
A1 Daiello, Lori A.
A1 Nakashima, Akitoshi
A1 Jash, Sukanta
A1 Huang, Zheping
A1 Drake, Jonathan D.
A1 Ernerudh, Jan
A1 Berg, Goran
A1 Padbury, James
A1 Saito, Shigeru
A1 Ott, Brian R.
A1 Sharma, Surendra
YR 2021
UL http://medrxiv.org/content/early/2021/03/20/2021.03.19.21253961.abstract
AB Non-invasive and sensitive blood test has long been a goal for early stage disease diagnosis and treatment for Alzheimer’s disease (AD) and other proteinopathy diseases. However, a blood test based on a mechanistic link to pathologic protein aggregate complexes has not been yet elucidated. We previously reported that preeclampsia (PE), a severe pregnancy complication, is another proteinopathy disorder with impaired autophagy. We hypothesized that induced autophagy deficiency would promote accumulation of pathologic protein aggregates. Here, we describe a novel, sensitive assay that detects serum protein aggregates from patients with PE as well as AD in both dementia and prodromal mild cognitive impairment (MCI) stages. The assay employs exposure of genetically engineered, autophagy-deficient human trophoblasts (ADTs) to serum from patients. The aggregated protein complexes and their individual components, including transthyretin, amyloid β-42, α-synuclein, and phosphorylated tau231, can be detected and quantified by co-staining with ProteoStat, a rotor dye with affinity to aggregated proteins, and respective antibodies. Autophagy-proficient human trophoblasts failed to accumulate serum protein aggregates under similar culture conditions. Detection of protein aggregates in ADTs was not dependent on transcriptional upregulation of these biomarkers. The ROC curve analysis validated the robustness of the assay for its specificity and sensitivity. In conclusion, we have developed a novel noninvasive diagnostic and predictive assay for AD, MCI and PE.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the NIH P20 GM121298, 3P20GM121298-04W1 and P30 GM114750 grants, Brown University DEANS Award, Brown University Seed Award, and William and Mary Oh-William and Elsa Zopfi Professorship Award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study is case control study and was approved by IRB committee of Women and Infants Hospital of Rhode Island (Project ID# WIH-02-0061). Informed written consent was obtained from each subject. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and/or analyzed during the current study are available from the corresponding authors on reasonable request.